DexCom, Inc. (DXCM) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is modestly constructive — consensus is a reasonable bar, the Q1 beat demonstrated operational discipline, and the biggest swing factor is whether new patient starts can sustain near-record momentum through the seasonally stronger back half.

Heading into Q2 2026, consensus expects DXCM to deliver revenue of approximately $1.29 billion (+11.5% YoY) and non-GAAP EPS of $0.61, both representing a modest step-up from Q1 actuals and consistent with management's full-year guidance of $5.16–$5.25 billion (11–13% growth). The bar is neither stretched nor easy: management reiterated full-year revenue guidance after Q1 despite beating, citing geopolitical commodity uncertainty (50–100 bps fuel/resin risk), which means the Street has not materially revised estimates upward — a slight cushion if execution holds. Tone has shifted meaningfully more confident since Q3 2025, with the May 2026 Investor Day delivering a long-range plan of 10%+ organic growth annually through 2030, a $1 billion share buyback (to be fully executed in 2026), and a CMS coverage decision expected "anytime between now and year-end" — all of which have been well-received and are reflected in the stock's +26% rally since Q1 earnings versus IHI +4% and SPY +2%. Estimate revisions have been essentially flat since the Q1 print, suggesting the market is waiting for Q2 execution to validate the LRP rather than pre-pricing further upside. The stock's re-rating has been driven primarily by multiple expansion on the CMS optionality and buyback announcement, not by estimate upgrades, which means the print itself needs to show continued new patient start momentum and gross margin stability to sustain the move. The key wildcard is CMS coverage timing: any signal — positive or negative — on a Medicare coverage decision for type 2 non-insulin users could move the stock more than the Q2 numbers themselves, given management's expectation of a decision before year-end and the potential to double the U.S. addressable market.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a reasonable, not stretched, bar — revenue and EPS estimates have barely moved since the Q1 print. New patient starts are the bigger swing factor: Q1 set a global record (305K), and Q2 consensus of ~304K implies near-record continuation; any shortfall here would be the most negative read-through for the full-year growth algorithm.

Table 1 — Q2 2026 Current Quarter Snapshot

Source: Visible Alpha Consensus and Actuals Data. Q1 2026 actuals from DXCM Q1 2026 earnings call (April 30, 2026). FY 2026 guidance from Q1 2026 earnings call and May 14, 2026 Investor Day 8-K.

Table 2 — Beat/Miss History (Last 8 Quarters)

Top KPI #1: Total Revenue | Top KPI #2: New Patient Starts

Pattern: DXCM has beaten revenue consensus in 7 of the last 8 quarters (the lone miss was Q2 2024, the quarter of the major guidance cut). New patient starts have beaten in 6 of 8 quarters, with the two misses (Q4 2024, Q4 2025) both occurring in seasonally strong quarters where the bar was set high. The consistent revenue beat cadence since Q3 2024 reflects a reset to a more conservative guidance framework post-Q2 2024.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Management raised operating margin and EBITDA margin guidance at Q1 2026 earnings while holding revenue and gross margin guidance unchanged — a deliberate, conservative posture citing geopolitical commodity risk. The May 2026 Investor Day was the more significant guidance event, introducing a 10%+ annual organic growth LRP through 2030 and a $1B buyback, materially shifting the long-term narrative.

Source: DXCM Q1 2026 Earnings Call transcript (April 30, 2026); Dexcom 2026 Investor Day 8-K and transcript (May 14, 2026).

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been essentially flat since the Q1 2026 print — revenue and EPS consensus for both Q2 and FY 2026 moved less than 0.5% in the ~12 weeks since the April 30 earnings. This is a healthy sign: the Street is not chasing the stock higher with estimate upgrades, leaving a modest cushion if Q2 execution is solid. The gap between consensus and guidance midpoint is narrow, suggesting the market is pricing in a clean quarter rather than a beat.

Estimates have barely moved since the Q1 print, which is unusual given the magnitude of the Investor Day announcements (LRP, buyback, CMS timing). The market appears to be treating the LRP as optionality rather than embedding it into near-term estimates — a rational stance given the binary nature of CMS coverage. The slight upward drift in new patient start estimates (+2.2%) reflects growing confidence in the G7 15-day adoption cycle.

Source: Visible Alpha Consensus and Actuals Data. Baseline as of May 7, 2026 (5 trading days post Q1 2026 earnings).

5. Stock Performance

Key Takeaway: DXCM has rallied +26.2% since Q1 2026 earnings (April 30) versus IHI +4.4% and SPY +1.5%, a dramatic outperformance driven almost entirely by multiple expansion on the Investor Day announcements (LRP, $1B buyback, CMS timing specificity) rather than estimate revisions. The stock's re-rating from ~$60 to ~$75 reflects the market pricing in CMS optionality and capital return credibility, not a change in near-term earnings power.

DXCM vs. IHI (iShares U.S. Medical Devices ETF) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings (April 30, 2026). Source: Yahoo Finance / Stock Price Data.

• April 30 — Q1 2026 Earnings: Stock opened at ~$59.55 (flat to slightly up after-hours). Beat on revenue (+1.4%) and a substantial EPS beat ($0.56 vs. $0.47 consensus). Operating and EBITDA margin guidance raised. Revenue guidance reiterated. Stock drifted sideways for two weeks as investors awaited Investor Day.
• May 14 — Investor Day (Mesa, AZ): The major catalyst. Stock surged from ~$58 to ~$65+ in the days following, then continued to ~$72 by May 22. Key announcements: 10%+ organic growth LRP through 2030, $1B buyback (fully executed in 2026), CMS coverage expected "anytime between now and year-end" with mid-2027 effective date assumed in LRP, 2030 gross margin target of 67–69%, G8 submission planned for 2027 with launch end-2027/early-2028.
• May–June — Consolidation: Stock traded in the $68–$78 range as the market digested the LRP. No material negative news; some profit-taking after the sharp post-Investor Day move.
• July 16 — Abbott Q2 2026 Earnings: ABT's CGM commentary (9.5% growth, CMS coverage "could happen in the fall") was a positive read-through for DXCM. Stock moved from ~$73 to ~$78 on July 16.
• July 28–29 — Pre-Earnings: Stock at ~$74–$75, up +26% since Q1 earnings. The stock has given back some of the July 16 spike but remains well above pre-Investor Day levels.

The performance has been driven by multiple expansion (CMS optionality, buyback credibility, LRP confidence) rather than estimate revisions. This creates a two-sided risk into Q2: a clean beat with positive new patient start commentary could sustain the multiple, but any revenue miss or cautious tone on CMS timing could compress it quickly given the stock's 26% run.

6. Peer Commentaries — Read-Through (Last 60 Days, Q2 2026 Relevant)

Key Takeaway: Three peer events in the last 60 days are directly relevant to DXCM's Q2 setup: Abbott's Q2 2026 earnings (July 16) confirmed CGM market growth is plateauing at 8–9% without reimbursement expansion but flagged CMS coverage "could happen in the fall" — the most important near-term catalyst for DXCM. Insulet's Q1 2026 earnings (May 6) and ADA investor event (June 8) confirmed robust type 2 diabetes device demand, strong new patient start momentum continuing into Q2, and no GLP-1 headwind to insulin-using patients — all constructive read-throughs for DXCM's new patient start trajectory.

Abbott Laboratories (ABT) — Q2 2026 Earnings Call (July 16, 2026)

Relevance: ABT is DXCM's primary CGM competitor (FreeStyle Libre). ABT's Q2 2026 earnings are the most timely and direct read-through for DXCM's Q2 2026 print, covering the same calendar quarter.

• CGM market growth plateauing at 8–9% without reimbursement expansion: ABT reported CGM sales exceeding $2 billion in Q2 2026, reflecting growth of 9.5%. CEO Robert Ford described this as a "market growth plateau" at "eight, 9% growth" in the absence of a major reimbursement expansion event. He framed this as still a good growth rate for an "approaching $10 billion business." Read-through for DXCM: Confirms the CGM market is growing but not accelerating without a coverage catalyst. DXCM's 11–13% FY 2026 guidance implies it is taking share from ABT, consistent with G7 15-day adoption and type 2 non-insulin coverage wins.
• CMS coverage "could happen in the fall": Ford stated that U.S. type 2 non-insulin CMS coverage "could happen in the fall," describing it as a "multibillion dollar opportunity" that would "unlock around 10 million Medicare beneficiaries" and "accelerate commercial insurance coverage." He noted this is "the number one" driver for unlocking CGM demand. Read-through for DXCM: This is the most important read-through. ABT's CEO independently corroborating DXCM management's "anytime between now and year-end" CMS timeline increases the probability of a near-term decision. A fall 2026 CMS decision would be a major positive catalyst for DXCM, potentially doubling the U.S. Medicare addressable market.
• 75–80 million global CGM-eligible patients, only 15 million currently on CGM: Ford highlighted the massive untapped opportunity: "you've got 75 to 80 million people around the world that could realistically be on a CGM and you've only got 15 million so far." He described this as "very sustainable" growth with "plenty of opportunity for growth acceleration." Read-through for DXCM: Validates DXCM's LRP assumption of 10%+ annual growth through 2030 and the long runway for new patient starts.
• International reimbursement expansion pipeline: ABT is in "active discussions with a dozen or so countries" on reimbursement introduction or expansion. France, Japan, and Canada cited as already broadly adopted. "Another seven markets" described as "pretty significant movers." Read-through for DXCM: Consistent with DXCM's international growth narrative (France and Canada cited as strongest Q1 2026 growth markets). Validates the international reimbursement expansion cycle as a multi-year tailwind.
• Abbott planning a fifth manufacturing facility (~$1B investment): ABT is in "final stages of planning" for a fifth 100-million-sensor facility, expecting to hit capacity at its fourth facility "in the next couple of years." Read-through for DXCM: Signals ABT is investing aggressively for long-term CGM growth, confirming the category's durability. Also signals ABT is not pulling back competitively.
• Libre Duo (dual glucose-ketone sensor) CE mark secured: ABT secured CE mark for Libre Duo in May 2026, with international rollout planned for fall 2026 and U.S. launch pending FDA approval. Read-through for DXCM: Competitive product innovation from ABT. DXCM is also integrating ketone sensing into G8 (post-launch). Near-term competitive impact is limited to international markets.

Insulet Corporation (PODD) — Q1 2026 Earnings Call (May 6, 2026)

Relevance: Insulet's Omnipod AID system integrates with DXCM's G7 sensor. PODD's Q1 2026 results (reported May 6) cover January–March 2026, providing a read-through on type 2 diabetes device demand and new patient start trends heading into Q2 2026. PODD raised its FY 2026 revenue growth guidance from 20–22% to 21–23% on the strength of Q1.

• Strong new patient start momentum continuing into Q2 2026: PODD reported U.S. new customer starts increased year-over-year in Q1 but declined sequentially due to deductible reset seasonality. Critically, management noted: "we saw U.S. new customer starts ramp through the quarter, and that momentum has continued into the second quarter." Read-through for DXCM: Intra-quarter momentum commentary from PODD (a major DXCM sensor partner) is a direct positive read-through for DXCM's Q2 new patient start trajectory. If AID new starts are ramping into Q2, CGM new starts should follow.
• Type 2 diabetes device demand remains robust; no GLP-1 headwind: PODD reported ~40% of new customer starts in Q1 were type 2, and stated: "we did not observe an impact from increased GLP use on type 2 NCS this quarter." Management reiterated that GLP-1s are "very complementary to AID therapy, not competitive," noting insulin use has remained stable at 26% of type 2 patients for nearly two decades despite GLP-1 use increasing tenfold. Read-through for DXCM: Directly addresses the key bear case for DXCM — that GLP-1 adoption reduces the CGM addressable market. PODD's data confirms insulin-using type 2 patients are not declining, supporting DXCM's type 2 non-insulin coverage expansion thesis.
• Libre 3 Plus integration expanding PODD's TAM by 450,000 patients: PODD announced integration with Abbott's Libre 3 Plus sensor, unlocking Omnipod 5 for ~450,000 Libre users. This is a competitive dynamic for DXCM — PODD is actively integrating with ABT's sensor, which could reduce DXCM's share of the AID-integrated CGM market. Read-through for DXCM: Modest competitive negative. DXCM remains the primary CGM partner for PODD's largest installed base, but ABT integration reduces DXCM's exclusivity in the AID channel.
• PODD raised FY 2026 guidance to 21–23% revenue growth: Strong Q1 execution (30% revenue growth, 28% U.S., 45% international) drove a guidance raise. Global customer base grew nearly 25% YoY. Read-through for DXCM: PODD's accelerating growth in the AID/CGM ecosystem is a positive category read-through. A rising tide of diabetes device adoption benefits DXCM as the leading CGM platform.
• MDI-to-AID conversion accelerating (now 80% of new starts from MDI, up from 60% four years ago): PODD highlighted the structural shift from multiple daily injections to AID, with MDI conversions now representing 80% of new customer starts. Read-through for DXCM: MDI converters to AID are a natural CGM adoption cohort. Accelerating MDI-to-AID conversion is a structural tailwind for DXCM new patient starts.

Insulet Corporation (PODD) — ADA Cardiometabolic Health Portfolio Investor Event (June 8, 2026)

Relevance: PODD's ADA investor event (June 8, 2026) provided detailed clinical data and market commentary directly relevant to DXCM's type 2 diabetes opportunity and competitive positioning heading into Q2 2026 earnings.

• GLP-1 data confirms insulin use is not declining: PODD presented new data from the Epic Cosmos database (through end of 2025) showing 41% of type 2 patients are on GLP-1, yet insulin use remains at 26% — unchanged from 2007. Among patients on GLP-1 alone, 43% had A1C >7%; among those on basal insulin alone, over half were not at target; among those on GLP-1 + MDI, 67% were not at target. Management concluded: "GLP-1 is not curing type 2 diabetes." Read-through for DXCM: Strongest available data point refuting the GLP-1 bear case for CGM. The insulin-using type 2 population is not shrinking, and the majority are not at glycemic target — exactly the population DXCM's type 2 non-insulin coverage expansion is targeting.
• Omnipod 5 algorithm enhancements released for U.S. market: PODD announced new algorithm enhancements including a lower glucose target of 100 mg/dL and improved alarm handling. Early data showed 2% improvement in time-in-range and 5% improvement in time-in-tight-range. For optimized settings, time-in-range reached up to 83%. Read-through for DXCM: Improved AID algorithm performance drives more patients to AID, which requires CGM. Positive category read-through for DXCM new patient starts.
• Omnipod 6 (Strive) pivotal data presented at ADA: Omnipod 6 showed 4% uplift in time-in-range (73% to 77%), 7% improvement in time-in-tight-range, and a 40% reduction in boluses with similar time-in-range in the bolus-optional phase. Omnipod 6 planned for launch in 2027. Read-through for DXCM: Omnipod 6 will be a major new patient start driver in 2027, and DXCM's G7/G8 sensors are the primary integration partners. Positive long-term read-through for DXCM's installed base growth.
• Fully closed-loop type 2 system (Evolve pivotal trial) now enrolling: PODD's Evolve pivotal trial for a fully closed-loop type 2 system (no bolus, no settings) has begun enrollment (~300 patients, 13-week trial). Feasibility data showed 66% time-in-range by week 6 from a 51% baseline, with no bolusing required. Submission planned for 2027, launch 2028. Read-through for DXCM: A fully closed-loop type 2 system would require CGM integration, expanding DXCM's addressable market in the type 2 insulin-using population. Positive long-term read-through, though 2028+ in timing.
• Primary care physician interest in AID is growing: PODD noted "a lot of interest from primary care providers who want to be offering more state of the art technology for their patients" and highlighted the sales force expansion of ~25% to deepen primary care engagement. Read-through for DXCM: Primary care physician adoption of AID/CGM is a key unlock for DXCM's type 2 non-insulin market. Growing PCP interest is a structural tailwind for DXCM's new patient start funnel.

7. Material News & Developments

Key Takeaway: The May 14 Investor Day was the most consequential post-Q1 development, resetting the long-term narrative with a credible 10%+ LRP and $1B buyback. The most important near-term catalyst remains CMS coverage timing, with Abbott's CEO independently flagging a potential fall 2026 decision.

• May 14, 2026 — Investor Day (Mesa, AZ): Dexcom hosted its 2026 Investor Day, delivering a comprehensive long-range plan through 2030. Key announcements: (1) 10%+ organic revenue growth every year through 2030 (not a CAGR — a minimum annual floor); (2) 2030 non-GAAP gross margin target of 67–69%, operating margin 29–30%, adj. EBITDA margin 36–37%; (3) $1.0 billion share repurchase authorization (fully executed in 2026, replacing prior $250M program; 50%+ of annual FCF to buybacks going forward); (4) CMS coverage decision expected "anytime between now and end of 2026" with mid-2027 effective date assumed in LRP; (5) G8 submission planned for 2027, launch end-2027/early-2028 (50% smaller form factor, 10%+ cost reduction vs. G7); (6) G7 15-day international rollout beginning H2 2026; (7) Dexcom Flex (new type 2 basal NIT product) pre-launched in Germany. Source: Dexcom 2026 Investor Day 8-K and transcript (May 14, 2026).
• May 14, 2026 — Governance Enhancements Announced: Dexcom announced governance enhancements ahead of the 2026 Investor Day, including board refreshment and enhanced shareholder engagement practices. Source: Dexcom press release (May 14, 2026).
• May 2026 — ADA 2026 Scientific Sessions (RCT Readout): The full readout of the randomized controlled trial (RCT) for CGM in type 2 non-insulin patients was presented at the ADA 2026 Scientific Sessions. Management had flagged this as the "defining study" for the population and a cornerstone for global payer evidence. Results were expected to support the CMS coverage case. Management noted the RCT "may not even be required" for CMS to act. Source: DXCM Q1 2026 Earnings Call (April 30, 2026).
• May 2026 — New Patch Technology Reaching Market: Dexcom began manufacturing with its new patch technology (FDA clearance received earlier in 2026), expected to reach market "in the coming weeks" from the Q1 earnings call. The upgraded adhesive is designed to strengthen sensor survivability and improve wear experience across the product portfolio. Source: DXCM Q1 2026 Earnings Call (April 30, 2026).
• Summer 2026 — Prime Therapeutics Coverage Effective: Prime Therapeutics began covering DexCom CGM for all people with diabetes effective summer 2026, adding approximately 1 million type 2 non-insulin lives to DXCM's commercial coverage. This puts DXCM on track for commercial coverage of more than 7 million type 2 non-insulin lives by year-end 2026. Source: DXCM Q1 2026 Earnings Call (April 30, 2026).
• July 9, 2026 — Q2 2026 Earnings Scheduled: Dexcom officially scheduled Q2 2026 earnings for July 30, 2026 at 4:30 PM ET. Source: Dexcom press release (July 9, 2026).
• July 16, 2026 — Abbott Q2 2026 Earnings (Peer Read-Through): Abbott CEO Robert Ford stated CMS type 2 non-insulin coverage "could happen in the fall," independently corroborating DXCM management's timeline. ABT's CGM business grew 9.5% in Q2 2026, consistent with the "market plateau" narrative absent a reimbursement catalyst. DXCM stock moved from ~$73 to ~$78 on the day. Source: ABT Q2 2026 Earnings Call (July 16, 2026).
• No analyst rating changes found in the period (April 30 – July 29, 2026).

8. Insider Transaction Activity

Key Takeaway: All open-market sales since Q1 earnings are 10b5-1 plan-driven — no discretionary selling. The volume of planned sales from Executive Chair Kevin Sayer (~53,500 shares, ~$3.8M) is notable in size but consistent with a pre-established plan. No open-market buys. The absence of discretionary selling and the presence of a large buyback program are the more meaningful signals.

All open-market sales (transaction code S) are flagged as 10b5-1 plan-driven (overall_10b5 = True). No discretionary open-market buys or sells were recorded in the period. The most notable activity is Executive Chair Kevin Sayer's two tranches of ~26,756–26,759 shares each (May 21 and July 6), totaling ~53,515 shares (~$3.8M at prevailing prices) — large in absolute dollar terms but consistent with a pre-established 10b5-1 plan and not a signal of insider concern. The $1B company buyback program announced at Investor Day is the more meaningful capital allocation signal.

Source: SEC Form 4 filings via Insider Transaction Data.